Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 1.00 |
| ▸ | BCL2 | P10415 | 9/20 | 1.00 |
| ▸ | MDM4 | O15151 | 1/20 | 1.00 |
| ▸ | BCL2L11 | O43521 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | BID | P55957 | 1/20 | 1.00 |
| ▸ | BAX | Q07812 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 1.00 |
| ▸ | ASPH | Q12797 | 1/20 | 1.00 |
| ▸ | BECN1 | Q14457 | 1/20 | 1.00 |
| ▸ | BAK1 | Q16611 | 1/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 1.00 |
| ▸ | BAD | Q92934 | 1/20 | 1.00 |
| ▸ | BBC3 | Q9BXH1 | 1/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.88 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.88 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.88 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.88 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.88 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt 737 SCHEMBL158942 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL170470 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL1541072 | 1.00 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540670 | 0.97 | BCL2L1 (0.93) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540214 | 0.96 | BCL2L1 (0.92) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540387 | 0.96 | BCL2L1 (0.92) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540510 | 0.96 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540736 | 0.96 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1541579 | 0.95 | BCL2L1 (0.91) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL26648550 | 0.95 | BCL2L1 (0.91) | BCL2L1BCL2MDM4BCL2L11TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268985-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | IMMUNE SYSTEM KEY LTD. (IL) | 2025-08-28 | — | — | US | claimed |
| WO-2025097150-A1 | BCL-2 INHIBITION TO AMPLIFY CHIMERIC ANTIGEN RECEPTOR THERAPY | THE UNIVERSITY OF CHICAGO (US) | 2025-05-08 | — | — | WO | claimed |
| EP-4507709-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | Immune System Key Ltd. (IL) | 2025-02-19 | — | — | EP | claimed |
| EP-4499101-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS OF USE OF AMINO-PYRROLOPYRIMIDINONE COMPOUND | Merck Sharp & Dohme LLC (US) | 2025-02-05 | — | — | EP | claimed |
| EP-4384171-A1 | COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES | JANSSEN Pharmaceutica NV (BE) | 2024-06-19 | — | — | EP | claimed |
| WO-2023199313-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | IMMUNE SYSTEM KEY LTD. (IL) | 2023-10-19 | — | — | WO | claimed |
| WO-2023192183-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS OF USE OF AMINO-PYRROLOPYRIMIDINONE COMPOUND | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023016995-A1 | COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | WO | claimed |
| WO-2026102277-A1 | COMBINATION THERAPIES COMPRISING IKZF2 DEGRADER COMPOUNDS | Plexium, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2026044294-A1 | COMPOSITIONS COMPRISING AN ANTI-MIR-126 NUCLEIC ACID AND BCL-2 HOMOLOGY 3 (BH3) MIMETIC AND METHODS OF USE | CITY OF HOPE (US) | 2026-02-26 | — | — | WO | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-11248028-B2 | Desmoglein 2 (DSG2) binding proteins and uses therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2022032132-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022019920-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | VERASTEM, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | BCL2L1 396/4885BCL2 1025/4885MDM4 1104/4885 |
| US-20250268985-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | BCL2, BCL2L13, BCL2L1 | BCL2L1 3/4885BCL2 1/4885MDM4 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.